For the quarter ending 2025-09-30, BGMSP had $701K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2024-12-31 |
|---|---|---|
| Net loss | -2,387 | -11,212 |
| Depreciation | 1 | 6 |
| Stock-based compensation | 1,679 | 592 |
| Gain on deconsolidation of subsidiary | 4,947 | - |
| Accounts receivable, net | 725 | - |
| Inventory | 1,368 | - |
| Prepaid expenses and other assets | -1,855 | - |
| Lease liability | 5 | -37 |
| Prepaid expenses and other assets | - | -4,472 |
| Accounts payable, accrued and other current liabilities | -8,744 | -1,811 |
| Net cash used in operating activities | -4,737 | -7,990 |
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 5,564 | 6,209 |
| Proceeds from the exercise of stock options and warrants, net of issuance costs | - | 1,613 |
| Payment of preferred stock dividend | 41 | - |
| Net cash provided by financing activities | 5,523 | 7,822 |
| Effect of exchange rate changes on cash and cash equivalents | -85 | -73 |
| Net increase (decrease) in cash and cash equivalents | 701 | -241 |
| Cash and cash equivalents at beginning of period | 3,137 | 3,378 |
| Cash and cash equivalents at end of period | 3,838 | 3,137 |
Bio Green Med Solution, Inc. (BGMSP)
Bio Green Med Solution, Inc. (BGMSP)